Sarepta Therapeutics Inc (SRPT)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Inventory turnover | 0.43 | 0.47 | 0.69 | 0.52 | 0.27 |
| Receivables turnover | — | — | — | — | — |
| Payables turnover | — | — | — | — | — |
| Working capital turnover | 0.81 | 0.65 | 0.48 | 0.33 | 0.26 |
Sarepta Therapeutics Inc's inventory turnover has shown an increasing trend over the years, indicating that the company is generating more revenue relative to its inventory levels. This suggests improved efficiency in managing inventory and selling products.
The data provided does not include information on receivables turnover and payables turnover, which makes it challenging to assess the efficiency of the company in collecting receivables from customers and managing payables to suppliers.
In terms of working capital turnover, Sarepta Therapeutics Inc has demonstrated a consistent and significant improvement from 0.26 in 2020 to 0.81 in 2024. This indicates that the company is effectively using its working capital to generate sales, highlighting efficient utilization of resources to drive revenue growth.
Overall, while Sarepta Therapeutics Inc shows positive trends in inventory turnover and working capital turnover, the absence of data on receivables and payables turnover limits a comprehensive analysis of the company's overall activity ratios and efficiency in managing working capital.
Average number of days
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 857.84 | 783.83 | 531.82 | 700.34 | 1,335.80 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — |
Based on the provided data, Sarepta Therapeutics Inc's activity ratios show varying trends over the years.
1. Days of Inventory on Hand (DOH):
- In 2020, Sarepta had a high DOH of 1,335.80 days, indicating a significant amount of inventory compared to sales.
- This improved in 2021 and further decreased in 2022 and 2023, reaching a low of 531.82 days.
- However, the DOH increased slightly in 2024 to 857.84 days, suggesting a potential increase in inventory relative to sales at the end of the period.
2. Days of Sales Outstanding (DSO):
- The DSO data was not provided, which makes it challenging to assess the efficiency of Sarepta's accounts receivable management over the years.
3. Number of Days of Payables:
- Similar to DSO, information on the number of days of payables was not available, limiting our analysis of Sarepta's accounts payable turnover and payment practices.
Overall, Sarepta seems to have made improvements in managing its inventory levels over the years, but additional information on receivables and payables would provide a more comprehensive view of the company's overall activity ratios and working capital management.
Long-term
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Fixed asset turnover | — | — | 3.81 | 3.67 | 2.84 |
| Total asset turnover | 0.48 | 0.38 | 0.30 | 0.22 | 0.18 |
The analysis of Sarepta Therapeutics Inc's long-term activity ratios based on the provided data shows an increasing trend in both the Fixed Asset Turnover and Total Asset Turnover ratios over the years.
1. Fixed Asset Turnover:
- The Fixed Asset Turnover ratio measures how efficiently the company is generating sales revenue from its investments in fixed assets.
- Sarepta's Fixed Asset Turnover has been steadily increasing from 2.84 in 2020 to 3.67 in 2021, further improving to 3.81 in 2022.
- However, there is no data available for 2023 and 2024, indicating a lack of information for those years regarding the company's fixed asset efficiency.
2. Total Asset Turnover:
- The Total Asset Turnover ratio assesses the company's ability to generate sales from its total assets.
- Sarepta's Total Asset Turnover has also shown a positive trend, increasing from 0.18 in 2020 to 0.22 in 2021, and further improving to 0.30 in 2022, 0.38 in 2023, and 0.48 in 2024.
- This signals that the company has been utilizing its assets more effectively to generate sales revenue over the years.
Overall, the rising trend in both the Fixed Asset Turnover and Total Asset Turnover ratios indicates that Sarepta Therapeutics Inc has been improving its efficiency in generating sales revenue relative to its investments in fixed assets and total assets, respectively, which is a positive sign for its operational performance and asset utilization efficiency.